Targeting pyroptosis reverses KIAA1199-mediated immunotherapy resistance in colorectal cancer
We found a critical role of KIAA1199 in promoting immunotherapy resistance by suppressing pyroptosis via the DNMT1/GSDME pathway in CRC. Decitabine has emerged as a promising therapeutic agent for reversing KIAA1199-mediated immunotherapy resistance by enhancing pyroptosis. Our findings provide valuable insights for enhancing the efficacy of immunotherapy in patients with CRC who exhibit resistance to conventional immunotherapy approaches.
Authors
- Diwei Zhou (ORCID: https://orcid.org/0000-0003-4323-7393)
- Dejun Zhang (ORCID: https://orcid.org/0000-0002-8623-5075)
- Jie Zheng (ORCID: https://orcid.org/0000-0002-6446-2250)
- Yuanhang Yu (ORCID: https://orcid.org/0009-0005-8839-2321)
- Jinghua Ren (ORCID: https://orcid.org/0000-0002-6931-0766)
- Tao� Zhang (ORCID: https://orcid.org/0000-0003-4018-3393)
- Pengfei Zhang (ORCID: https://orcid.org/0000-0003-3470-085X)
- Lisha Li (ORCID: https://orcid.org/0000-0003-4048-5981)
- Jing Zhang (ORCID: https://orcid.org/0000-0002-7120-9827)
- Pengfei Zhou (ORCID: https://orcid.org/0000-0003-2181-3804)
- Zhenyu Lin (ORCID: https://orcid.org/0000-0002-1733-5806)
- Dandan Yu (ORCID: https://orcid.org/0000-0003-2578-7324)
- Lei Zhao (ORCID: https://orcid.org/0000-0003-2876-4347)
Institutions
- Union Hospital (HK)
- Wuhan YZY Biopharma (China) (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/jitc-2024-010000
- Citations
- 7
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 5.64
Funders
- National Natural Science Foundation of China